Floatz logo

Rfix

Severe Hemophilia B

Bioverativ Therapeutics Inc.Phase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Severe Hemophilia B cohort.

Asset / SponsorPhaseRating
EFTRENONACOG ALFA
Bioverativ Therapeutics Inc.
Phase 3BB

Same molecule, other indications

Rfix is also rated in:

hemophilia BDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →